387 related articles for article (PubMed ID: 14529538)
1. New insights into the molecular mechanisms of action of bisphosphonates.
Rogers MJ
Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
[TBL] [Abstract][Full Text] [Related]
2. Cellular and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
4. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
7. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
Roelofs AJ; Thompson K; Ebetino FH; Rogers MJ; Coxon FP
Curr Pharm Des; 2010; 16(27):2950-60. PubMed ID: 20722616
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
Rogers MJ; Mönkkönen J; Munoz MA
Bone; 2020 Oct; 139():115493. PubMed ID: 32569873
[TBL] [Abstract][Full Text] [Related]
10. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
13. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
17. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonates: the molecular targets and mechanisms of action].
Wada S; Kamiya S; Ono K
Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
